Literature DB >> 17591933

The human androgen receptor X-chromosome inactivation assay for clonality diagnostics of natural killer cell proliferations.

Michaël Boudewijns1, Jacques J M van Dongen, Anton W Langerak.   

Abstract

Clonality is a frequently exploited characteristic of lymphoid malignancies. However, in the natural killer (NK) cell subset of large granular lymphocyte proliferations, clonality is difficult to prove because of the lack of specific genetic markers, such as immunoglobulin or T-cell receptor gene rearrangements. The human androgen receptor (HUMARA) assay, a polymerase chain reaction-based X-chromosome inactivation assay, is a potential diagnostic tool in these disorders. Although there is much experience with X-chromosome inactivation assays in myeloid proliferations, these assays have found only very limited application in clonality assessment of NK cell proliferations. We applied the HUMARA assay in laboratory diagnostics for detection of clonality in NK cell proliferations. We describe its test performance and report three cases in which clonality of NK cell populations was investigated by use of this assay. Our results demonstrate the usefulness of the HUMARA assay in the diagnostic workup of NK cell proliferations.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17591933      PMCID: PMC1899426          DOI: 10.2353/jmoldx.2007.060155

Source DB:  PubMed          Journal:  J Mol Diagn        ISSN: 1525-1578            Impact factor:   5.568


  41 in total

1.  Evidence for the polyclonal nature of focal nodular hyperplasia of the liver by the study of X-chromosome inactivation.

Authors:  V Paradis; A Laurent; J F Flejou; M Vidaud; P Bedossa
Journal:  Hepatology       Date:  1997-10       Impact factor: 17.425

2.  Clonal studies of CD3- lymphoproliferative disease of granular lymphocytes.

Authors:  R Nash; P McSweeney; R Zambello; G Semenzato; T P Loughran
Journal:  Blood       Date:  1993-05-01       Impact factor: 22.113

3.  Hypermethylation of the M27beta (DXS255) locus in chronic B-cell leukaemia.

Authors:  P E Crossen; M J Morrison
Journal:  Br J Haematol       Date:  1998-01       Impact factor: 6.998

4.  Nonrandom X-inactivation patterns in normal females: lyonization ratios vary with age.

Authors:  L Busque; R Mio; J Mattioli; E Brais; N Blais; Y Lalonde; M Maragh; D G Gilliland
Journal:  Blood       Date:  1996-07-01       Impact factor: 22.113

5.  The lymphoproliferative disease of granular lymphocytes: updated criteria for diagnosis.

Authors:  G Semenzato; R Zambello; G Starkebaum; K Oshimi; T P Loughran
Journal:  Blood       Date:  1997-01-01       Impact factor: 22.113

6.  Tissue specificity of X-chromosome inactivation patterns.

Authors:  R E Gale; H Wheadon; P Boulos; D C Linch
Journal:  Blood       Date:  1994-05-15       Impact factor: 22.113

7.  PCR bias in amplification of androgen receptor alleles, a trinucleotide repeat marker used in clonality studies.

Authors:  G L Mutter; K A Boynton
Journal:  Nucleic Acids Res       Date:  1995-04-25       Impact factor: 16.971

8.  Clonality of CD3 negative large granular lymphocyte proliferations determined by PCR based X-inactivation studies.

Authors:  A Kelly; S J Richards; M Sivakumaran; C Shiach; A D Stewart; B E Roberts; C S Scott
Journal:  J Clin Pathol       Date:  1994-05       Impact factor: 3.411

9.  Methylation of HpaII and HhaI sites near the polymorphic CAG repeat in the human androgen-receptor gene correlates with X chromosome inactivation.

Authors:  R C Allen; H Y Zoghbi; A B Moseley; H M Rosenblatt; J W Belmont
Journal:  Am J Hum Genet       Date:  1992-12       Impact factor: 11.025

10.  Quantification of X-chromosome inactivation patterns in haematological samples using the DNA PCR-based HUMARA assay.

Authors:  R E Gale; C A Mein; D C Linch
Journal:  Leukemia       Date:  1996-02       Impact factor: 11.528

View more
  12 in total

1.  EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes.

Authors:  J J M van Dongen; L Lhermitte; S Böttcher; J Almeida; V H J van der Velden; J Flores-Montero; A Rawstron; V Asnafi; Q Lécrevisse; P Lucio; E Mejstrikova; T Szczepański; T Kalina; R de Tute; M Brüggemann; L Sedek; M Cullen; A W Langerak; A Mendonça; E Macintyre; M Martin-Ayuso; O Hrusak; M B Vidriales; A Orfao
Journal:  Leukemia       Date:  2012-05-03       Impact factor: 11.528

2.  Variability of cross-tissue X-chromosome inactivation characterizes timing of human embryonic lineage specification events.

Authors:  Jonathan M Werner; Sara Ballouz; John Hover; Jesse Gillis
Journal:  Dev Cell       Date:  2022-07-31       Impact factor: 13.417

3.  Chronic natural killer lymphoproliferative disorders: characteristics of an international cohort of 70 patients.

Authors:  E Poullot; R Zambello; F Leblanc; B Bareau; E De March; M Roussel; M L Boulland; R Houot; A Renault; T Fest; G Semenzato; T Loughran; T Lamy
Journal:  Ann Oncol       Date:  2014-08-05       Impact factor: 32.976

4.  Screening for clonal hematopoiesis as a predictive marker for development of therapy-related myeloid neoplasia (t-MN) following neoadjuvant therapy for breast cancer: a Southwest Oncology Group study (S0012).

Authors:  Marilyn L Slovak; Victoria Bedell; Danika Lew; Kathy S Albain; Georgiana K Ellis; Robert B Livingston; Silvana Martino; Edith A Perez; Gabriel N Hortobagyi; Dorie Sher; Wendy Stock
Journal:  Breast Cancer Res Treat       Date:  2010-01       Impact factor: 4.872

5.  Epigenomics and Single-Cell Sequencing Define a Developmental Hierarchy in Langerhans Cell Histiocytosis.

Authors:  Florian Halbritter; Matthias Farlik; Raphaela Schwentner; Gunhild Jug; Nikolaus Fortelny; Thomas Schnöller; Hanja Pisa; Linda C Schuster; Andrea Reinprecht; Thomas Czech; Johannes Gojo; Wolfgang Holter; Milen Minkov; Wolfgang M Bauer; Ingrid Simonitsch-Klupp; Christoph Bock; Caroline Hutter
Journal:  Cancer Discov       Date:  2019-07-25       Impact factor: 39.397

6.  Systemic Erdheim-Chester disease.

Authors:  Brendan Craig Dickson; Vaijayanti Pethe; Catherine Tse-Shing Chung; David John Charles Howarth; Juan Manuel Bilbao; Victor Lodovico Fornasier; Catherine Joanne Streutker; Linda Marilyn Sugar; Bharati Bapat
Journal:  Virchows Arch       Date:  2008-01-10       Impact factor: 4.535

7.  Complete remission in a patient with JAK2- and IDH2-positive myelofibrosis.

Authors:  Lucia Masarova; Wei Wang; Kate J Newberry; Hagop Kantarjian; Srdan Verstovsek
Journal:  Blood       Date:  2016-06-20       Impact factor: 25.476

8.  Linking the KIR phenotype with STAT3 and TET2 mutations to identify chronic lymphoproliferative disorders of NK cells.

Authors:  Cédric Pastoret; Fabienne Desmots; Gaëlle Drillet; Simon Le Gallou; Marie-Laure Boulland; Alexia Thannberger; Anne-Violaine Doncker; Véronique Salaun; Gandhi Laurent Damaj; Richard Veyrat-Masson; Olivier Tournilhac; Aline Moignet; Céline Pangault; Mikaël Roussel; Thierry Fest; Thierry Lamy
Journal:  Blood       Date:  2021-06-10       Impact factor: 25.476

9.  Loss-of-function mutations in the X-linked biglycan gene cause a severe syndromic form of thoracic aortic aneurysms and dissections.

Authors:  Josephina A N Meester; Geert Vandeweyer; Isabel Pintelon; Martin Lammens; Lana Van Hoorick; Simon De Belder; Kathryn Waitzman; Luciana Young; Larry W Markham; Julie Vogt; Julie Richer; Luc M Beauchesne; Sheila Unger; Andrea Superti-Furga; Milan Prsa; Rami Dhillon; Edwin Reyniers; Harry C Dietz; Wim Wuyts; Geert Mortier; Aline Verstraeten; Lut Van Laer; Bart L Loeys
Journal:  Genet Med       Date:  2016-09-15       Impact factor: 8.822

10.  Xp11.22 deletions encompassing CENPVL1, CENPVL2, MAGED1 and GSPT2 as a cause of syndromic X-linked intellectual disability.

Authors:  Christina Grau; Molly Starkovich; Mahshid S Azamian; Fan Xia; Sau Wai Cheung; Patricia Evans; Alex Henderson; Seema R Lalani; Daryl A Scott
Journal:  PLoS One       Date:  2017-04-17       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.